证券日报网讯1月8日，寿仙谷（603896）在互动平台回答投资者提问时表示，公司将继续坚守主业，开 拓市场，努力以更好的业绩回报全体投资者的信任与支持。后续，公司将结合实际情况继续推出股东回 馈活动，敬请关注公司公告。 ...

Core Viewpoint - The straw industry in China is deeply integrated with agriculture, energy, chemicals, and building materials, forming various industrial chains that enhance rural employment and farmers' income while creating indirect economic value through the substitution of petrochemical and wood resources [2][10]. Market Policy - The Chinese government has implemented a series of policies to promote comprehensive utilization of straw, including subsidies, market construction, and incentive measures, providing a favorable policy environment for the development of the straw recycling and processing industry [2][10][12]. - Key policies include the "Air Quality Continuous Improvement Action Plan," which emphasizes the comprehensive utilization of straw and the prohibition of burning, aiming to stabilize the comprehensive utilization rate of straw above 86% [12][10]. Utilization Volume and Rate - The comprehensive utilization of straw in China is projected to increase from 555 million tons in 2024 to 647 million tons, with feed usage accounting for approximately 18.4%, raw material and substrate fields about 1.8%, edible fungus substrate around 2.3%, and fuel fields about 8.2% [2][10]. - The comprehensive utilization rate of straw is expected to rise from 77.7% in 2024 to 88.3%, with the market size growing from 147.63 billion yuan to 205.10 billion yuan [2][10]. Industry Chain - The straw industry chain in China consists of three levels: upstream resource supply and equipment manufacturing, midstream processing and technology conversion, and downstream diversified applications, moving towards scale, high value, and intelligence [13][14]. - The upstream includes straw resource sources, collection, storage, and machinery, while the midstream focuses on processing and technology conversion, leading to applications in agriculture, energy, building materials, and environmental protection [13][14]. Related Companies - Listed companies involved in the straw industry include Sierte (002538), Yili Group (600887), Huarui Agriculture (833462.NQ), Xuerong Biological (300511), Shouxiangu (603896), Disen Co. (300335), Changqing Group (002616), Sun Paper (002078), and Shengquan Group (605589) [2].

（编辑 楚丽君） 证券日报网讯 1月6日，寿仙谷在互动平台回答投资者提问时表示，寿仙谷灵芝里是由公司投资的商业 综合体，是公司探索品牌体验与渠道创新、推动营销改革的重要举措。该综合体核心定位是"寿仙谷国 医药馆名医、名药、名店+餐饮+娱乐"多维业态融合的县域消费核心引擎与文化客厅。 ...

Core Viewpoint - The company, Shouxiangu (603896), aims to deepen its focus on the field of food and medicine homology, emphasizing product innovation and channel expansion to enhance its national brand influence and create long-term value for investors [1] Group 1 - The company will continue to innovate its products in the food and medicine homology sector [1] - The company plans to expand its distribution channels to reach a broader audience [1] - The goal is to enhance the brand's national influence [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 证券代码：603896 | 证券简称：寿仙谷 | | --- | --- | | 债券代码：113660 | 债券简称：寿 转债 22 | | | 公告编号：2026-001 | 浙江寿仙谷医药股份有限公司 关于"寿 22 转债"转股结果暨股份变动的公告 根据《上海证券交易所股票上市规则》等有关法律法规的规定和《浙江寿仙 谷医药股份有限公司公开发行可转换公司债券募集说明书》的约定，"寿 22 转债" 转股期自 2023 年 5 月 23 日至 2028 年 11 月 16 日止（如遇法定节假日或休息日延 至其后的第 1 个工作日；顺延期间付息款项不另计息）。"寿 22 转债"的初始转 股价格为 38.08 元/股；因实施公司 2022 年度权益分派，"寿 22 转债"转股价格 自 2023 年 7 月 4 日由 38.08 元/股调整为 37.65 元/股；因实施公司 2023 年度权益 分派，"寿 22 转债"转股价格自 2024 年 6 月 20 日由 3 ...

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the sector [5]. Core Insights - The market performance for the Chinese medicine sector showed a slight decline of 1.67% last week, which is relatively smaller compared to other pharmaceutical segments [1]. - The price-to-earnings (PE) ratio for the Chinese medicine sector is reported at 26.63X, with a slight decrease of 0.45X week-on-week, indicating a valuation within the historical range [2]. - The demand for tonic herbs continues to grow, leading to a slight increase in the Chinese medicinal herb price index, which rose by 0.1% last week [3]. - The integration of Chinese medicinal pieces into a national drug traceability code system is accelerating, which is expected to enhance the quality and management of the industry [4]. Summary by Sections Market Performance - The Chinese medicine sector index closed at 6234.32 points, down 1.67% last week, while the overall pharmaceutical sector index fell by 2.06% [1][11]. - Notable companies with strong performance include Wanbangde, Tianmu Pharmaceutical, and Guhang Medicine, while underperformers include *ST Changyao and ST Hulahua [1][17]. Valuation - The current PE ratio for the Chinese medicine sector is 26.63X, with a year-to-date maximum of 30.26X and a minimum of 24.72X [2]. - The price-to-book (PB) ratio stands at 2.24X, with a year-to-date maximum of 2.52X and a minimum of 2.17X [2]. Industry Trends - The demand for tonic herbs is on the rise, contributing to a slight increase in the price index for Chinese medicinal herbs [3]. - The national drug traceability system for Chinese medicinal pieces is being implemented, which is expected to improve the quality and traceability of medicinal materials [4]. Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [5]. - Specific investment targets include companies with strong R&D capabilities, unique products, and those less affected by price reductions due to centralized procurement [9].

（编辑 楚丽君） 证券日报网讯 12月30日，寿仙谷在互动平台回答投资者提问时表示，寿仙谷是国内最早将航天育种技 术系统应用于珍稀中药材育种的企业之一，拥有长达二十余年的实践经验。截至2025年12月30日，公司 已先后七次与国家级航天项目合作，成功将灵芝、铁皮石斛等珍稀药材的种子或菌种送入太空，并成功 培育出"仙芝2号""仙斛3号"灵芝及铁皮石斛优良新品种。公司始终坚守"科研立企"战略，通过搭建全产 业链科研创新平台，将航天科技与传统中医药智慧相结合。未来公司将继续以科技创新为引擎，持续探 索商业航天技术赋能中医药产业的更多可能性，为消费者提供更优质的大健康产品，为投资者创造长期 价值。 ...

Group 1 - The core viewpoint of the news is that Zhejiang Shouxiangu Pharmaceutical Co., Ltd. has shown a stock price increase of 1.24%, reaching 19.56 CNY per share, with a total market capitalization of 3.878 billion CNY [1] - The company specializes in the breeding, cultivation, processing, and sales of precious Chinese medicinal materials, including Ganoderma lucidum and Dendrobium officinale, with its main business revenue composition being 71.92% from Ganoderma spore powder products, 15.57% from Dendrobium products, and 10.88% from other sources [1] Group 2 - Among the top ten circulating shareholders of Shouxiangu, the Rongtong Health Industry Flexible Allocation Mixed A/B fund has increased its holdings by 82,300 shares in the third quarter, now holding 1.2823 million shares, which accounts for 0.65% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund has a current scale of 1.816 billion CNY, with a year-to-date return of 9.15% and a one-year return of 4.6% [2] Group 3 - The fund manager of Rongtong Health Industry Flexible Allocation Mixed A/B is Wan Minyuan, who has a total fund asset scale of 5.957 billion CNY, with the best fund return during his tenure being 132.72% and the worst being -25.09% [3]

Meeting Overview - The second extraordinary general meeting of shareholders was held on December 23, 2025, at the company's location in Zhejiang Province [2] - The meeting was convened by the board of directors, with the chairman, Mr. Li Mingyan, presiding over the meeting [2][3] - The meeting was witnessed by lawyers from Zhejiang Tiance Law Firm, ensuring compliance with legal and regulatory requirements [7] Attendance and Voting - A total of 9 directors were present, with 7 attending the meeting; two directors were absent due to official duties [3] - The voting process adhered to the Company Law and the company's articles of association, with all resolutions passed in accordance with the required majority [2][4] Resolutions Passed - The following proposals were approved during the meeting: 1. The 2026 annual routine related party transaction plan [4] 2. The application for a comprehensive credit limit and related guarantee matters for 2026 [4] 3. The use of temporarily idle raised funds and self-owned funds for cash management in 2026 [5] 4. The revision of the remuneration management system for directors and senior management [5] - Proposal 2 was classified as a special resolution, requiring approval from more than two-thirds of the voting rights held by shareholders present [5][6] Legal Opinion - The legal opinion provided by the witnessing lawyers confirmed that the meeting's procedures, participant qualifications, and voting processes complied with relevant laws and regulations [7]

（编辑 王雪儿） 证券日报网讯 12月23日，寿仙谷发布公告称，公司2025年第二次临时股东会审议通过《浙江寿仙谷医 药股份有限公司2026年度日常关联交易预案》《关于公司申请2026年度综合授信额度及相关担保事项的 议案》等多项议案。 ...